Research Analysts Issue Forecasts for Valeo Pharma Inc.’s Q1 2024 Earnings (TSE:VPH)

Valeo Pharma Inc. (TSE:VPHFree Report) – Analysts at Echelon Wealth Partners reduced their Q1 2024 earnings estimates for shares of Valeo Pharma in a research report issued to clients and investors on Monday, February 5th. Echelon Wealth Partners analyst S. Quenneville now anticipates that the company will post earnings of ($0.08) per share for the quarter, down from their previous estimate of ($0.06). Echelon Wealth Partners also issued estimates for Valeo Pharma’s Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.04) EPS and FY2024 earnings at ($0.21) EPS.

Valeo Pharma Price Performance

Shares of TSE:VPH opened at C$0.18 on Thursday. The firm has a market capitalization of C$17.76 million, a PE ratio of -0.56 and a beta of 2.62. The firm’s 50-day moving average is C$0.23 and its two-hundred day moving average is C$0.24. Valeo Pharma has a 1 year low of C$0.13 and a 1 year high of C$0.60.

About Valeo Pharma

(Get Free Report)

Valeo Pharma Inc, a specialty pharmaceutical company, engages in the acquisition, in-licensing brands, and sale of pharmaceuticals and hospital specialty products for unmet medical needs in Canada. Its product portfolio includes Enerzair Breezhaler, a LABA/LAMA/ICS fixed triple dose asthma drug; Atectura Breezhaler, a LABA/ICS dual combination asthma drug; Redesca, to treat and prevent deep vein thrombosis and pulmonary embolism; Onstryv, for the treatment of Idiopathic Parkinson's disease; M-Eslon, extended-release morphine sulphate used for pain management; and Yondelis, a soft tissue sarcoma.

Further Reading

Receive News & Ratings for Valeo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.